In conclusion, treatment of patients with symptomatic CHF and anemia with ESPs results in significant improvements in hospitalization rate, Hb, Hct and BNP levels, mortality, exercise capacity, renal function, NYHA class and LVEF. This evidence concerns the gene GSTM1 and congestive heart failure.